DJIA 17,712.94 -33.04 -0.19%
NASDAQ 5,136.80 8.01 0.16%
S&P 500 2,106.15 -2.48 -0.12%
market minute promo

554.68 7.58 (1.39%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

REGN $554.68 1.39%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $551.29
Previous Close $547.10
Daily Range $547.85 - $558.50
52-Week Range $310.69 - $569.92
Market Cap $57.3B
P/E Ratio 175.35
Dividend (Yield) $0.00 (0.0%)
Volume 252,053
Average Daily Volume 626,295
Current FY EPS $8.31

Sector

Healthcare

Industry

Drug Makers

Regeneron Pharmaceuticals, Inc. (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website: http://www.regeneron.com/

News & Commentary Rss Feed

Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval

The FDA has given the nod to the sale of Praluent, the first of a new class of cholesterol lowering medications, and a blockbuster opportunity for the company's.

Sanofi Tops Q2 Earnings, Revenues Grow Y/Y, Maintains View - Analyst Blog

The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases

Regeneron's Mega-Blockbuster Potential With Praluent: CVS Health Sees It, So Why Don't More Analysts

Regeneron's Mega-Blockbuster Potential With Praluent: CVS Health Sees It, So Why Don't More Analysts?

Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog

Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceu

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases

Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches

US Stock Futures Surge Ahead Of Fed Meeting

Regeneron Pharmaceuticals CEO Boasts Recently Approved Cholesterol-Lowering Drug

See More REGN News...

REGN's Top Competitors

REGN $554.68 (1.39%)
Current stock: REGN
AMGN $177.29 (3.26%)
Current stock: AMGN
GILD $117.67 (-0.20%)
Current stock: GILD
BIIB $319.51 (0.79%)
Current stock: BIIB